Seventy percent of postmenopausal women experience vasomotor symptoms, which can be highly disruptive and persist for years; 10% describe them as intolerable.^[@R1],[@R2]^ For the majority of participants in the MsFLASH 02 study, the two most bothersome symptoms of menopause were vasomotor symptoms and sleep disturbance.^[@R3]^ Hormone therapy and other alternative treatments, including some antidepressants, gabapentin, cognitive behavioral therapy, and herbal remedies, have variable efficacy and/or limited availability, and/or significant adverse profiles with recommended contraindications for some women including those with a history of breast cancer for example.^[@R4]-[@R8]^ As such a novel therapeutic that safely and effectively treated hot flashes (HFs) could benefit millions of women worldwide.

Scientific research has changed our understanding of HF etiology over the last 20 years with two critical findings. The first was the role of specialized hypothalamic neurons that colocalize kisspeptin, neurokinin B (NKB), and dynorphin receptors (KNDy neurons) across the reproductive lifespan^[@R9]^; and the second was the work of Rance and colleagues who have elucidated the neurocircuitry of hypothalamic NKB signaling together with its receptor, the neurokinin 3 receptor (NK3R), in the thermoregulatory autonomic system in response to estrogen deficiency.^[@R10]-[@R15]^ Two recent publications further implicate NKB/NK3R signaling in menopausal flushing: (1) peripheral administration of NKB in premenopausal women resulted in HFs that were typical of those described by postmenopausal women,^[@R16]^ and (2) a population-based study suggested genetic variation in *TACR3*, the gene that encodes NK3R could be associated with the variability in vasomotor symptoms experienced by postmenopausal women.^[@R17]^ Collectively, the prior literature led us to hypothesize that NKB/NK3R signaling is critical in menopausal flushing. We therefore carried out a study to determine whether vasomotor symptoms in postmenopausal women could be attenuated by administration of an oral NK3R antagonist. This trial completed earlier this year and confirmed that an NK3R antagonist can reduce HFs in postmenopausal women after 4 weeks of treatment.^[@R18]^ In this article we report novel data from that study, which shows the detailed time course of this effect.

METHODS
=======

Study design and participants
-----------------------------

This randomized, double-blind, placebo-controlled, single-center, crossover study recruited women aged 40 to 62 years who were having at least seven flashes/24-h period (of which some were reported as being severe or bothersome), and who had not had a menstrual period for at least 12 months (Clinicaltrials.gov NCT02668185). Sixty-eight women were screened, of which 45 were confirmed eligible to enter the study which started with a 2-week baseline "run in" period to establish "steady state" and familiarity with recording symptoms.^[@R18]^ Thirty-seven participants were confirmed to be eligible to enter the active phase of the study, and so received 4 weeks of treatment with an oral selective NK3R antagonist twice daily (MLE4901; Millendo Therapeutics, Inc., Ann Arbor, MI) and 4 weeks of exact-match placebo twice daily in the order generated by central randomization separated by a 2-week washout period (Fig. [1](#F1){ref-type="fig"}).^[@R18]^ Participants were ambulatory during the study and no restriction was placed on lifestyle. Full details outlining inclusion and exclusion criteria and study design are as previously described.^[@R18]^ Approvals were granted by the West London Regional Ethics Committee (15/LO/1481), and the Medicine and Healthcare Products Regulatory Agency (EudraCT 2015-001553-32). The trial was registered in full at ClinicalTrials.gov before study start (NCT02668185), and performed in accordance with Good Clinical Practice Guidelines.

![Summary of protocol: baseline period: participants underwent a 2-week period to gather baseline data on hot flush (HF) frequency, HF severity, HF bother, and perceived HF interference (Hot Flash-Related Daily Interference Scale). If the inclusion criteria regarding HF frequency and severity were met at the end of this period, then they were assigned to the active phase of the study after randomization (black circle). Intervention 1 (double-blind): all participants randomized to either 4 weeks of treatment with oral, 40 mg twice daily MLE4901 or exact-match placebo. Washout period: all participants underwent a 2-week washout period after intervention 1 (half-life of MLE4901 is 8.5 h). Intervention 2 (double-blind): all participants then switched to receive either four weeks treatment with oral twice daily exact-match placebo or oral 40 mg twice daily MLE4901 depending on which intervention they received first. Monitoring period: a subsequent 2-week period to complete safety monitoring. Figure available under the terms of the CC BY licence from <http://dx.doi.org/10.1016/S0140-6736(17)30823-1> (Prague et al, *Lancet*, 2017^[@R18]^).](menop-25-862-g001){#F1}

Outcomes
--------

The primary outcome was total number of HFs during the fourth week of treatment with MLE4901 and placebo. Secondary outcomes included HF severity, bother, interference, reproductive hormone concentrations, Menopause-Specific Quality of Life (MENQOL) domain scores, and objective measurement of HFs using a skin conductance monitor (Bahr monitor). HF frequency, severity, and bother data were collated twice daily to capture symptoms that occurred during the daytime and those that occurred during the nighttime separately. For all outcomes, outlined a priori in our protocol, comparison was made between the average daily value during the fourth week of treatment with MLE4901 and placebo, and also between the average daily value during the fourth week of both treatment periods and the second week of the baseline period. Full details outlining study design methodology are as previously described.^[@R18]^ Post hoc time course analysis was subsequently conducted to ascertain the therapeutic profile of MLE4901 by comparing mean daily total at day 3, and mean weekly total after week 1, week 2, week 3, and week 4 of both treatment periods, and also compared with the second week of the baseline period. To assess the impact on sleep, post hoc analyses were completed on daytime and nighttime vasomotor symptoms separately, and a selection of individual MENQOL and Hot Flash Related Daily Interference Scale (HFRDIS) items (MENQOL: "difficulty sleeping," "lethargy," "tiredness," "stamina," "muscle ache," "physical strength"; HFRDIS: "sleep," "concentration"). All post hoc analyses are reported in this article.

Statistical analysis
--------------------

Our a priori statistical plan was strictly followed as previously described^[@R18]^; in summary, analyses were completed for the intention-to-treat (ITT; *n* = 37) and per-protocol (*n* = 28) data sets using generalized linear mixed models and standard crossover analysis to estimate the adjusted (least squares) means, and differences between treatment means, together with associated 95% CIs and *P* value. A similar approach was used for our post hoc analyses in our modified ITT cohort using only observed data rather than an imputation technique (therefore using a minimum of *n* = 33 and maximum *n* = 35 out of a total number of 37 participants, except for percentage change from baseline for the HFRDIS items "sleep" and "concentration" where the minimum was *n* = 27 due to 7 participants scoring 0 at baseline). Data were analyzed using generalized linear mixed models with an unstructured covariance matrix. For all models used, a standard crossover analysis was implemented with period, administration sequence, and treatment as fixed effects and subject as a random effect as previously described.^[@R18]^ In the a priori analyses, the final model only necessitated inclusion of the baseline value as a covariate.^[@R18]^ Similarly, our post hoc analyses only required the baseline value as a covariate as well. For each subject, the percentage change from baseline was calculated at each time point, with baseline defined from the data captured during the second week of the baseline period. The percentage change from baseline was then analyzed using the above-described generalized linear mixed model. From each model, as before, adjusted (least squares) means and differences between treatment means were estimated, together with associated 95% CIs, and a *P* value from a comparison of the mean values of the two treatments.^[@R18]^ Post hoc analyses of linear correlation calculated the Pearson correlation coefficient. A priori sample size and power calculation were performed using published data from studies with similar methodology; including an anticipated 25% improvement in symptoms with placebo^[@R19]-[@R23]^ as previously described.^[@R18]^

Funding
-------

This was an academic investigator initiated and led study, which was funded by the UK Medical Research Council (grant reference MR/M024954/1) and an National Institute for Health Research Professorship to WSD (grant reference RP-2014-05-001).

RESULTS
=======

Full results of the a priori outcomes (mean HF frequency, severity, bother, interference, MENQOL domains, and sweat monitor data during the final week of the 4-wk treatment period with MLE4901 and placebo), luteinizing hormone pulsatility, and safety data are as previously reported.^[@R18]^

Post hoc analysis of questionnaire data (minimum *n* = 33 participants, maximum *n* = 35 participants) demonstrated that by day 3 of treatment with MLE4901, HF frequency reduced by 72% compared with baseline (95% CI, −81.3 to −63.3%; 51 percentage point decrease compared with placebo, *P* \< 0.0001) and this effect size persisted throughout the 4-week dosing period. HF severity, bother, and interference, however, continued to improve throughout dosing. At day 3 HF severity reduced by 38% compared with baseline (95% CI, −46.1 to −29.1%; 31 percentage point reduction compared with placebo, *P* \< 0.0001), which then reduced further to −43% by day 14 and −44% by day 28 (39 percentage point reduction compared with placebo); bother reduced by 39% (95% CI, −47.5 to −30.1; 34 percentage point reduction compared with placebo, *P* \< 0.0001), which then reduced further to −45% by day 14 and −50% by day 28 (46 percentage point reduction compared with placebo), and interference reduced by 61% (95% CI, −79.1 to −43.0%; 37 percentage point reduction compared with placebo, *P* = 0.0006), which then reduced further to −64% by day 14 and −70% by day 28 (40 percentage point reduction compared with placebo) (for full time course data, see Fig. [2](#F2){ref-type="fig"}; day 28 data as previously reported \[ITT: *n* = 37\]^[@R18]^). Continued improvement in HF symptoms over the 4-week period of treatment was not seen with placebo (Fig. [2](#F2){ref-type="fig"}). HF frequency, severity, and bother were all positively correlated (*r* = 0.76-0.93, *P* \< 0.0001). HF interference was also positively correlated with frequency, severity, and bother, but the strength of association was weaker (*r* = 0.62-0.65, *P* \< 0.0001). Post hoc analysis also demonstrated that a similar improvement in HF symptoms was achieved during the daytime as during the nighttime after treatment with MLE4901, and again the improvement was rapid (Table [1](#T1){ref-type="table"}).

![Hot flash frequency (A), severity (B), bother (C), and interference (D) outcomes: results are presented as percentage change with 95% CIs from baseline at each time point during the treatment period (ie, on day 3 of treatment, and then weekly mean total for each week (wk) of the 4-week treatment period for both placebo (white) and MLE4901 (gray). Minimum *n* = 33; maximum *n* = 37. ^∗^*P* \< 0.0001, ^\#^*P* = 0.0006, ^\^^*P* = 0.0011, ^+^*P* = 0.0001. Week 4 data adapted from Prague et al, *Lancet*, 2017^[@R18]^.](menop-25-862-g002){#F2}

###### 

Hot flash frequency, severity, and bother during day time and night time

              Daytime vasomotor symptoms   Night vasomotor symptoms                                                                                                                                   
  ----------- ---------------------------- -------------------------- ---- -------------------- ------------------- ---------- ---- -------------------- ---- -------------------- ------------------ ----------
  Frequency                                                                                                                                                                                           
   Day 3      34                           −25% (−35 to −16%)         34   −75% (−85 to −66%)   −50 (−62 to −38)    \<0.0001   34   −16% (−29 to −4%)    34   −70% (−83 to −57%)   −54 (−70 to −37)   \<0.0001
   Week 1     34                           −24% (−33 to −15%)         35   −72% (−80 to −63%)   −48 (−59 to −37)    \<0.0001   34   −18% (−29 to −4%)    35   −63% (−72 to −54%)   −45 (−57 to −33)   \<0.0001
   Week 2     34                           −29% (−38 to −19%)         34   −81% (−91 to −71%)   −52 (−66 to −39)    \<0.0001   34   −22% (−33 to −11%)   34   −75% (−86 to 63%)    −52 (−69 to −36)   \<0.0001
   Week 3     34                           −30% (−40 to −19%)         34   −82% (−93 to −71%)   −52 (−67 to −37)    \<0.0001   34   −28% (−38 to −17%)   34   −76% (−86 to −65%)   −48 (−63 to −33)   \<0.0001
   Week 4     34                           −29% (−40 to −18%)         34   −82% (−93 to −72%)   −53 (−68 to −38)    \<0.0001   34   −22% (−35 to −10%)   34   −78% (−90 to −65%)   −55 (−72 to −39)   \<0.0001
  Severity                                                                                                                                                                                            
   Day 3      33                           −4% (−13 to 5%)            34   −40% (−48 to −31%)   −36 (−47 to −24)    \<0.0001   33   −6% (−16 to 4%)      35   −37% (−47 to −27%)   −31 (−44 to −18)   \<0.0001
   Week 1     34                           −4% (−10 to 3%)            35   −38% (−44 to −32%)   −34 (−42 to −26)    \<0.0001   34   −1% (−8 to 6%)       35   −35% (−42 to −28%)   −34 (−43 to −25)   \<0.0001
   Week 2     34                           −8% (−15 to −0.4%)         34   −43% (−50 to −36%)   −36 (−46 to −26)    \<0.0001   34   −4% (−12 to 4%)      34   −43% (−51 to −36%)   −40 (−50 to −29)   \<0.0001
   Week 3     34                           −7% (−14 to −0.4%)         34   −47% (−54 to −41%)   −40 (−49 to −31)    \<0.0001   34   −4% (−12 to 3%)      34   −46% (−53 to −38%)   −41 (−51 to −32)   \<0.0001
   Week 4     34                           −8% (−15 to −1%)           34   −45% (−52 to −38%)   −37 (−46 to −29)    \<0.0001   34   −3% (−11 to 5%)      34   −47% (−55 to −39%)   −44 (−54 to −34)   \<0.0001
  Bother                                                                                                                                                                                              
   Day 3      34                           −7% (−16 to 1%)            33   −42% (−51 to −33%)   −35 (−47 to −23)    \<0.0001   33   −6% (−16 to 4%)      35   −37% (−47 to −27%)   −31 (−45 to −17)   0.0001
   Week 1     34                           −7% (−14 to −1%)           35   −40% (−47 to −34%)   −33 (−41 to − 24)   \<0.0001   34   −2% (−9 to 5%)       35   −36% (−43 to −29%)   −33 (−43 to −24)   \<0.0001
   Week 2     34                           −9% (−17 to −2%)           34   −47% (−55 to −40%)   −38 (−48 to −28)    \<0.0001   34   −5% (−13 to 3%)      34   −44% (−52 to −36%)   −40 (−51 to −28)   \<0.0001
   Week 3     34                           −10% (−17 to −4%)          34   −50% (−57 to −44%)   −40 (−49 to −31)    \<0.0001   34   −7% (−14 to 1%)      34   −46% (−54 to −39%)   −40 (−50 to −29)   \<0.0001
   Week 4     34                           −9% (−15 to −3%)           34   −51% (−58 to −45%)   −42 (−51 to −33)    \<0.0001   34   −5% (−13 to 3%)      34   −48% (−56 to −40%)   −43 (−54 to −32)   \<0.0001

Results are presented as percentage change with 95% CIs from baseline on day 3 of treatment and mean weekly total for each week (week 1, week 2, week 3, and week 4) for both placebo and MLE4901 and treatment periods. Daytime symptoms: all symptoms from the time of getting up to going to bed; nighttime symptoms: all symptoms from going to bed to getting up the following morning.

The psychosocial and physical domains of the MENQOL questionnaires significantly improved as a result of treatment with MLE4901.^[@R18]^ Post hoc analysis suggested that this was due to improved sleep as items less likely to be related to this such as "muscle ache" and "physical strength" were not significantly different (*P* = 0.3685 and *P* = 0.7808, respectively) after treatment with MLE4901, whereas those more likely to be related to improved sleep such as "difficulty sleeping," "tiredness," and "lethargy" were (*P* \< 0.0001, *P* = 0.0019, and *P* = 0.0175, respectively) (Table [2](#T2){ref-type="table"}). Improvements in sleeping, tiredness, and lethargy were significant by day 3 of treatment with MLE4901. Similar results were seen in post hoc analysis of two of the individual items of the HF-related daily interference score (HFRDIS): both "sleep" and "concentration" (*n* = 27-29 as 7 participants scored 0 at baseline) significantly improved with treatment with MLE4901, and again as early as day 3 ( Table [3](#T3){ref-type="table"}). There was a linear concordance between the two sleep items in the two questionnaire measures "difficulty sleeping" in MENQOL and "sleep" in HFRDIS (*r* = 0.70, *P* \< 0.0001).

###### 

Questionnaire items from MENQOL which either are or are not likely related to improved sleep

  MENQOL item           *n*   Placebo (PBO)        *n*   MLE4901 (MLE)        Percentage point difference (MLE-PBO)   *P*
  --------------------- ----- -------------------- ----- -------------------- --------------------------------------- ------------------------------------------------
  Difficulty sleeping                                                                                                 
   Day 3                34    14% (−23 to 50%)     34    −16% (−52 to 21%)    −29 (−66 to 7)                          0.1111[^*a*^](#TF2-1){ref-type="table-fn"}
   Week 1               34    16% (−10 to 42%)     35    −13% (−39 to −13%)   −29 (−57 to −1)                         *0.0463*[^*a*^](#TF2-1){ref-type="table-fn"}
   Week 2               34    12% (−6 to −30%)     34    −30% (−48 to −12%)   −41 (−63 to −20)                        *0.0006*[^*a*^](#TF2-1){ref-type="table-fn"}
   Week 3               34    2% (−14 to −19%)     34    −34% (−51 to −18%)   −37 (−57 to −16)                        *0.0012*[^*a*^](#TF2-1){ref-type="table-fn"}
   Week 4               34    14% (−4 to 32%)      34    −42% (−60 to −24%)   −56 (−80 to −32)                        *\<0.0001*[^*a*^](#TF2-1){ref-type="table-fn"}
  Lethargy                                                                                                            
   Day 3                34    3% (−11 to 18%)      35    −15% (−29 to −1%)    −18 (−37 to 0)                          *0.0474*
   Week 1               34    −2% (−13 to 9%)      35    −13% (−24 to −2%)    −11 (−22 to 1)                          0.0608
   Week 2               34    1% (−9 to 10%)       34    −13% (−23 to −3%)    −14 (−25 to −2)                         *0.0233*
   Week 3               34    1% (−13 to 15%)      34    −15% (−28 to −1%)    −16 (−33 to 1)                          0.0657
   Week 4               34    6% (−9 to 20%)       34    −17% (−32 to −3%)    −23 (−41 to −5)                         *0.0128*
  Tiredness                                                                                                           
   Day 3                34    −6% (−19 to 8%)      35    −18% (−31 to −5%)    −13 (−22 to −3)                         *0.0132*
   Week 1               34    −0.1% (−11 to 11%)   35    −16% (−27 to −5%)    −16 (−26 to −5)                         *0.0042*
   Week 2               34    0.4% (−11 to 12%)    34    −15% (−27 to −3%)    −15 (−28 to −3)                         *0.0210*
   Week 3               34    −0.4% (−12 to 12%)   34    −23% (−36 to 13%)    −23 (−37 to −9)                         *0.0023*
   Week 4               34    1% (−10 to −12%)     34    −24% (−36 to −12%)   −25 (−37 to −13)                        *0.0002*
  Stamina                                                                                                             
   Day 3                34    2% (−18 to 22%)      35    −10% (−30 to 11%)    −12 (−38 to 15)                         0.3730
   Week 1               34    4% (−8 to 16%)       35    −6% (−18 to 7%)      −9 (−23 to 5)                           0.1790
   Week 2               34    9% (−3 to 21%)       34    −2% (−14 to 10%)     −11 (−22 to 1)                          0.0693
   Week 3               34    9% (−6 to 24%)       34    −6% (−20 to 10%)     −15 (−33 to 4)                          0.1177
   Week 4               34    5% (−10 to 19%)      34    −7% (−21 to 7%)      −12 (−26 to 3)                          0.1044
  Muscle ache                                                                                                         
   Day 3                34    4% (−17 to 25%)      34    −1% (−22 to 20%)     −5 (−33 to 24)                          0.7278
   Week 1               34    12% (−10% to 33%)    35    13% (−8 to 35%)      2 (−19 to 22)                           0.8680
   Week 2               34    15% (−10 to 40%)     34    25% (−1 to 50%)      10 (−9 to 28)                           0.2938
   Week 3               34    10% (−17 to 38%)     34    16% (−12 to 43%)     5 (−14 to 25)                           0.5813
   Week 4               34    15% (−14 to 43%)     34    22% (−7 to −50%)     7 (−9 to 23)                            0.3685
  Physical strength                                                                                                   
   Day 3                34    −1% (−11 to 9%)      35    −1% (−12 to 9%)      0 (−6 to 6)                             0.9346
   Week 1               34    2% (−7 to 11%)       35    0.2% (−9 to 9%)      −2 (−10 to 6)                           0.5934
   Week 2               34    5% (−6 to 15%)       34    −2% (−13 to 8%)      −7 (−18 to 5)                           0.1810
   Week 3               34    12% (−6 to 29%)      34    −2% (−20 to 16%)     −13 (−37 to 10)                         0.2507
   Week 4               34    −2% (−14 to 10%)     34    −4% (−16 to 9%)      −2 (−13 to 10)                          0.7808

Results are presented as percentage change with 95% CIs from baseline on day 3 of treatment and mean weekly total for week 1, week 2, week 3, and week 4 of the treatment periods for both placebo and MLE4901.

^*a*^Skewed data. Italics---significant *P* value.

MENQOL, Menopause-Specific Quality of Life.

###### 

Questionnaire items from HFRDIS which are likely related to improved sleep

  HFRDIS item     *n*   Placebo (PBO)       *n*   MLE4901 (MLE)         Percentage point difference (MLE-PBO)   *P*
  --------------- ----- ------------------- ----- --------------------- --------------------------------------- ------------------------------------------------
  Sleep                                                                                                         
   Day 3          28    −16% (−45 to 13%)   28    −72% (−101 to −43%)   −56 (−97 to −15)                        *0.0010*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 1         28    −16% (−41 to 8%)    28    −61% (−86 to −36%)    −46 (−80 to −10)                        *0.0148*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 2         28    −11% (−34 to 13%)   27    −70% (−94% to −47%)   −60 (−93 to −27)                        *0.0011*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 3         28    −14% (−38 to 11%)   27    −67% (−93 to −42%)    −54 (−85 to −22)                        *0.0017*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 4         28    −20% (−42 to 1%)    27    −82% (−104 to −60%)   −62 (−93 to −32)                        *0.0003*[^*a*^](#TF3-1){ref-type="table-fn"}
  Concentration                                                                                                 
   Day 3          29    −25% (−46 to −4%)   29    −67% (−88 to −46%)    −42 (−72 to −12)                        *0.0075*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 1         29    −20% (−39 to −1%)   29    −55% (−74 to −36%)    −35 (−62 to −9)                         *0.0118*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 2         29    −13% (−37 to 11%)   29    −59% (−83 to −35%)    −46 (−81 to −12)                        *0.0099*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 3         29    −4% (−35 to 28%)    29    −56% (−87 to −24%)    −52 (−80 to −25)                        *0.0007*[^*a*^](#TF3-1){ref-type="table-fn"}
   Week 4         29    −14% (−32 to 4%)    29    −77% (−95 to −58%)    −62 (−88 to −37)                        *\<0.0001*[^*a*^](#TF3-1){ref-type="table-fn"}

Results are presented as percentage change with 95% CIs from baseline on day 3 of treatment and mean weekly total for week 1, week 2, week 3, and week 4 of the treatment periods for both placebo and MLE4901.

^*a*^Skewed data. Italics---significant *P* value.

HFRDIS, Hot Flash Related Daily Interference Scale.

DISCUSSION
==========

In this post hoc analysis we have demonstrated that an oral NK3R antagonist (MLE4901) rapidly, and effectively, reduced frequency, severity, bother, and interference of vasomotor symptoms. Furthermore, similar improvements were seen in daytime and nighttime symptoms, and participants also experienced significant improvement in sleep. Considering that in the MsFLASH 02 study vasomotor symptoms and sleep were the two foremost symptom priorities for participants, these findings are particularly important^3^, and further advance the understanding of the specific therapeutic profile of NK3R antagonists both on symptomatology and speed of onset. Importantly, treatment was also well tolerated.^[@R18]^

It is difficult to compare the onset of action with other currently available treatments for vasomotor symptoms as the preexisting trials have only reported "end of study" data. For example, the reported data for hormone therapy in trials range from 3 months to 3 years,^[@R24]^ for paroxetine is after 6 weeks of treatment,^[@R25]^ and for gabapentin is after 12 weeks of treatment.^[@R26]^ Mean weekly total for week 1 was slightly worse than the total for day 3 in all outcomes after treatment with MLE4901 and this is likely because the weekly total was an average that included days 1 and 2 of treatment. Interestingly, participants anecdotally reported a noticeable change in their symptoms after approximately 48 hours of starting treatment with MLE4901, and also reported a similar time to offset on cessation.

It is also difficult to conclude to what extent the improvement in sleep and concentration were a result of less disruption through the night as flashes were less frequent and/or less severe/bothersome, so overall sleep quality was improved, or as a result of a direct effect on neuronal pathways involved in sleep by MLE4901. It is plausible that both explanations are contributory to the improvement in symptoms; especially as prior research has shown that melanin-concentrating hormone neurons, which are involved in the sleep--wake cycle, express NK3R.^[@R27],[@R28]^ Furthermore, NK3R has also been shown to be present in the prefrontal cortex, which is an important brain area for concentration,^[@R29]^ and a prior meta-analysis suggested that hormone therapy may improve cognitive function in young women,^[@R30]^ though this was disputed in the WHI Memory Study^[@R31]^ but methodological differences may explain this disparity in findings. Further study in larger clinical trials of NK3R antagonists, as well as preclinical studies, may help to provide mechanistic and symptomatic detail.

As per previous studies the placebo effect was sizeable (28% reduction in HF frequency, which is similar to the reported rate in the literature of 25%), and this is why it is critical for trials investigating new treatments for vasomotor symptoms to be placebo controlled. The treatment effect size of MLE4901 above that achieved by placebo (percentage point reduction compared with placebo) was, however, highly significant for all outcomes. Although direct comparison with other available treatments is problematic as outlined above, our data suggest that the treatment effect of MLE4901 is similar to that of hormone therapy, and superior to that achieved by standard prescription doses of paroxetine or gabapentin,^[@R24]-[@R26]^ and thus is likely to be clinically meaningful.

Our results fit entirely with the preexisting data that have implicated NKB/NK3R signaling as a critical mediator of menopausal vasomotor symptoms. From the early work by Rance et al in postmortem brain specimens that demonstrated the marked hypertrophy and increased activity of hypothalamic neurons with upregulated NKB gene expression,^[@R15]^ to the more recent first report in a clinical trial of inducing typical flashes in premenopausal women by infusing NKB peripherally.^[@R16]^ Mechanistically, it seems clear that it is the subsequent increased activation of/input to the thermoregulatory autonomic pathway via increased NKB/NK3R signaling through the median preoptic nucleus in response to estrogen withdrawal that is critical.^[@R10]-[@R14]^ This heightened signaling pathway can seemingly now be silenced by pharmacological blockade with an oral NK3R antagonist, and thus vasomotor symptoms can be attenuated to the significant benefit of otherwise deeply affected women. Moreover, this can be achieved rapidly, and without the need for estrogen exposure making it a more attractive, or even clinically possible, option for many women than conventional hormone therapy. Furthermore, there may be additional health benefits of treatment with a NK3R antagonist for postmenopausal women. Cardiovascular disease for example is increased in women after estrogen levels decline, and there is some evidence that administering an NK3R antagonist in rats reverses spontaneous hypertension and lowers heart rate,^[@R32]^ and that this effect is achieved by reducing midbrain dopaminergic signaling in the ventral tegmental area that highly expresses NK3R.^[@R33]^ The NK3R is also present on vasopressin neurons,^[@R34]^ and neurokinin B activity has been shown to be potentiated by thromboxane A2.^[@R35]^ This hypothesis would need to be tested in very large clinical trials that were adequately powered for cardiovascular endpoints but if possible they could be highly informative, and offer a novel treatment strategy for a leading cause of mortality and morbidity.^[@R36]^

CONCLUSIONS
===========

The novel data that we report in this manuscript, which details the time course of the effect of an NK3R antagonist to relieve menopausal symptoms and the impact on sleep, fit entirely with the preexisting literature and are timely as there is significant interest in the NK3R antagonist class as a future therapeutic for vasomotor symptoms.^[@R37]^ Larger scale studies assessing efficacy, safety, and optimal dosing strategy are already underway. If these studies are also positive and provide good long-term safety data, then this novel approach of using NK3R antagonism to treat menopausal flushing will be practice changing.
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